360° Coverage : Hedging Strategies in a Hot Biotech Market (Secrets of the Buy...

2 Updates

Hedging Strategies in a Hot Biotech Market (Secrets of the Buy Side)

Mar 5 2014, 9:20am CST | by

For fun, go to your Bloomberg terminal and pull up a chart for Curagen (CRGN), then type in “GPO M”. This will bring up a price chart from 1998 until the company was acquired by Celldex (CLDX) in...

Filed under: news


32 weeks ago

Hedging Strategies in a Hot Biotech Market (Secrets of the Buy Side)

Mar 5 2014, 9:20am CST | by

For fun, go to your Bloomberg terminal and pull up a chart for Curagen (CRGN), then type in “GPO M”. This will bring up a price chart from 1998 until the company was acquired by Celldex (CLDX) in 2009. Focus on the period from 2000 to 2002.

This is everyone’s biotech bubble nightmare right now.

Is the biotech sector in a bubble? I claim no competence in gauging the wisdom – or whatever you call it – of the masses.

Is the sector “hot?” Undoubtedly.

So what do we do to prevent our portfolios from doing a Curagen?

Protecting stock gains is not as simple a process as one may think (nor is profiting from the reversal of what may be a bullish market for that matter.) You don’t want to depress the price of your stocks by selling your own position, something that portfolio managers face when they own a large position in a relatively illiquid name. Second, while tax considerations should not override fundamentals in trading decisions, they should not be ignored. The United States tax code gives us incentives to hold positions for more than one year, because the tax on capital gains is substantially less than the tax on short-term gains. Third, none of us wants to be overcautious. For those of us who invest based on fundamentals, one stock at a time, we should not overestimate our ability to predict large sector movements when that type of prediction is not a core competence.

So what do we do to prevent our portfolios from doing a Curagen?

One possibility is to ignore everything I said two paragraphs back and take a large short position in a sector index fund or exchange traded fund (ETF). This makes sense insofar as a big downward movement in the biotech or life sciences sector will be reflected in poor performance of the index or the ETF.

The problem with that strategy is that sector indices are often poor reflections of your underlying portfolio. If I were to try to hedge my portfolio, which consists of approximately 40 small and microcap names, with a sector index or ETF, I would be hedging small cap with large cap. The available indices for biotechnology are disproportionately weighted with companies like Gilead (GILD), Biogen Idec (BIIB), Celgene (CELG) and Amgen (AMGN). These stocks move in very different ways than my predominantly pre-revenue, early-stage, small-cap names. This trade could easily blow up if, whether or not the market for biotech rose or fell, a megamerger of a large pharma company and one of a large biotech companies were to occur, or if a company like Alexion (ALXN) were to be acquired. Further, the cash flow positive names that populate the indices are easy to fit into the discounted cash flow equations that analysts rely upon for price targets. This results in stock price movements that remain confined to more narrow bands than the price movements of my small cap names.

So how about choosing a portfolio of the similarly market cap weighted names that we think are fundamentally weaker, selling those names short, and moving to a more normal market neutral portfolio where our short exposure matches are long exposure?

This theoretically sound strategy, like the index hedging strategy we discussed, is much more difficult in practice than in theory.

Without naming any names, we all know companies whose weak fundamentals seem to disconnect from their share price performance. The stock market is an irrationally irrational place, and expecting engineering-type cause-and-effect relationships is an exercise in frustration. This is a particularly acute problem when identifying small company stocks to sell short. The most disastrous long position will lose 100% of its value, assuming it was bought without leverage (a rule that I feel every small cap investor should follow.) A disastrous short sale, on the other hand, is truly a house on fire.

The market can irrationally price a stock at five dollars a share, and then cruelly punish those rational value investors who, clutching their worn copies of Benjamin Graham’s “The Intelligent Investor,” short the stock at 5 and watch the market irrationally push stock price to 10, or 15 or higher. And, unlike a long position which grows less painful as it goes against you since each percentage movement in the wrong direction chips away at shrinking principle, a short position gets more and more and more painful the longer it stubbornly refuses to go by the book.

Even we fundamental investors try to avoid short squeezes.

So you want to know what to do to prevent your portfolio from doing a Curagen?

Part two to come.

(By the way, I don’t mean to pick on Curagen, which was actually founded by brilliant people and did some good for the world during its corporate life. I just needed a scary chart from a company that no longer trades.)

Source: Forbes Business


7 weeks ago

Khazanah throws MAS RM6b lifeline

Aug 29 2014 5:01pm CDT | Source: Business Times Singapore

August 30, 2014 1:15 AMKHAZANAH Nasional will inject RM6 billion (SS$2.4 billion) over three years to resuscitate loss-making Malaysia Airlines (MAS) under a recovery plan that includes even an Act of Parliament. Other key moves are migrating its operations, assets and liabilities to a new company (NewCo) and slashing the workforce of 20,0 ...
Source: Business Times Singapore   Full article at: Business Times Singapore


7 weeks ago

MAS posts loss of RM307m for Q2

Aug 28 2014 5:00pm CDT | Source: Business Times Singapore

August 29, 2014 1:13 AMMALAYSIA Airlines (MAS) registered a loss of RM307 million (S$122 million) for the second quarter to end-June, but warned of worse to come in the second half when the "full financial impact of the doub ...
Source: Business Times Singapore   Full article at: Business Times Singapore


Don't miss ...


<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.


blog comments powered by Disqus

Latest stories

Ebola-infected Spanish nurse continues 'favourable progress'
Madrid, Oct 19 (IANS) Teresa Romero, the 44-year-old Spanish nursing auxiliary who was the first person to be infected by the Ebola virus in Spain, continues to show favourable progress three weeks after first developing symptoms of the illness and a fortnight after being admitted into the Carlos III Hospital in Madrid.
Japanese firm eyes algae-based shampoo
Tokyo, Oct 19 (IANS) Japanese household goods maker Kao Corp. may soon be using algae to produce cleansing agents for its products, specifically shampoo, media reported Sunday.
iPhone app to ensure eye health
Washington, Oct 19 (IANS) Researchers have successfully used an iPhone app for imaging the inside of the eye of immobile and paediatric patients.
How the birth season can trigger mood disorders
London, Oct 19 (IANS) The risk of developing mood disorders is impacted by the season in which you are born in, a research showed.

Latest from the Network

Bush shoe-tossing painting hits record at Doha auction
Doha, Oct 15 (IANS/EFE) A controversial painting by Iranian artist Mahmud Obaidi, depicting an Iraqi journalist throwing shoe in 2008 at then US president George W. Bush, was sold for $62,500 at a Sotheby's auction in...
Read more on Celebrity Balla
US offers $45 mn bounty for eight terror leaders
Washington, Oct 15 (IANS) The US said Tuesday it is offering rewards totalling up to 45 million dollars for information on eight key leaders of the Al Qaeda in the Arabian Peninsula (AQAP) terrorist organisation. The...
Read more on Politics Balla
UNSC extends peacekeeping mission's term in Abyei
United Nations, Oct 15 (IANS) The UN Security Council (UNSC) has renewed the mandate of the UN peacekeeping mission in the Abyei border region between Sudan and South Sudan. In an unanimously adopted resolution, the...
Read more on Politics Balla
Ebola cases in West Africa could reach 10,000 per week: WHO
Geneva, Oct 15 (IANS) The World Health Organisation (WHO) has warned that the Ebola epidemic in West Africa could reach 5,000 to 10,000 cases per week by the first week of December. "Quite frankly, ladies and...
Read more on Business Balla
Turkey, Singapore sign strategic partnership agreement
Ankara, Oct 15 (IANS) Turkey and Singapore have signed a strategic partnership agreement to boost economic, political and cultural cooperation, as well as security collaboration, during the official visit of...
Read more on Politics Balla
Christina Aguilera is returning to 'The Voice' USA
Christina Aguilera will return to 'The Voice' USA next year. The 'Your Body' hitmaker, who previously shared a rotating spot on the judging panel with Shakira, has been replaced by Gwen Stefani this season as she is...
Read more on Celebrity Balla
Kesha's music producer hits back
Kesha is being countersued by her record company boss, Dr. Luke. The 41-year-old music producer, who runs Kemosabe Records, claims the 27-year-old 'Tik Tok' singer is a liar and is trying to extort him after she accused...
Read more on Celebrity Balla
Jason Derulo won't get back together with Jordin Sparks
Jason Derulo insists his split from Jordin Sparks is permanent. The 'Talk Dirty' hitmaker, who recently ended his relationship with the 'No Air' singer after three years of dating, has ruled out getting back together...
Read more on Celebrity Balla
Josh Groban feels 'very lucky' to be dating Kat Dennings
Josh Groban feels ''very lucky'' to be dating Kat Dennings. The 'Brave' hitmaker was very nervous before singing in front of the '2 Broke Girls' actress for the first time at the Carousel of Hope Ball in Beverly Hills,...
Read more on Celebrity Balla
Australian Richard Flanagan wins 2014 Man Booker prize
London, Oct 15 (IANS) The first Man Booker prize to allow American nominees was Tuesday night won by an Australian, with Richard Flanagan triumphing for a novel of love and war that tells the harrowing stories of...
Read more on Celebrity Balla